Recently, Medtronic (NYSE:MDT) Announces First Patient Successfully EnrolledOnyxLiquid Embolic System (LES) ofPELETest.

PELEThe full name of the trial is "Peripheral Onyx Liquid Embolic”，Aimed to evaluateOnyx LESSafety of Embolization of Peripheral Vascular System Arterial Bleeding.This trial is of great significance, with the first surgery performed byChristopher StarkThe Ph.D. was successfully completed at Albany Medical Center, marking the beginning of the entire research.

Onyx LESIs a type of ethylene- Vinyl Alcohol (EVOH) copolymer, which has unique performance advantages. It can completely fill and penetrate distally into peripheral lesion areas, and under fluoroscopic control, it can be precisely delivered to the target site via a microcatheter.The system has non-adhesive properties, which significantly reduces the risk of the catheter getting stuck during distal lesion embolization, providing more convenience and safety for surgical procedures. Additionally, its higher viscosity design allows doctors to achieve controlled deployment, further enhancing the precision of the treatment.

Researchers have a rigorous experimental plan, intending to conduct studies across numerous sites in the United States.25Recruit up to119Patients participated in the study. During the30Within a number of days, the primary safety and efficacy endpoints will be the key focus of the assessment. The trial includes subjects who are considered suitable candidates for embolization therapy to treat active arterial bleeding in the peripheral vasculature. The peripheral vasculature referred to here explicitly excludes blood vessels in the brain and heart, primarily focusing on the vascular systems of other parts of the body.

Medtronic has high hopes for this trial and plans to use the data obtained from it to fully demonstrateOnyx LESThe advantage is that the system will be included in its peripheral vascular embolization product portfolio.Currently,Onyx LESEmbolization of peripheral vascular system arterial bleeding is still in the research stage in the United States, but in many markets outside the U.S., it already has peripheral indications.

President of Medtronic's Peripheral Vascular Health BusinessDavid MoellerSaid: "Onyx LESHas been applied in the peripheral treatment field in many markets outside the United States. This timePELEThe trial will be used by doctors in the United States.Onyx"Provide necessary evidence support for arterial bleeding in the peripheral vascular system, which is a key step in advancing our embolization product portfolio strategy."

WithPELEAs the trial continues to advance, we look forward to seeing more aboutOnyx LESThe system's research achievements in the treatment of arterial bleeding in the peripheral vascular system bring patients safer and more effective treatment options.